NEWS
Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial
Ensysce Biosciences (NASDAQ:ENSC)has initiated dosing in the PF614-MPAR-102 study, marking a significant milestone for its breakthrough therapy-designated opioid drug.
The trial aims to evaluate the pharmacokinetics of oxycodone and PF614 when co-administered with nafamostat.
The study received a $14 million multi-year award from NIDA and expects early interim data in Q1 2025.
The three-part trial will assess the full dosage range, food effects, and conduct multi-ascending dose studies of PF614-MPAR, which is designed to reduce deliberate and accidental overdoses in severe pain treatment.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2958Followers
109Following
31KVisitors
Follow
Lnova : I’m looking at this one today
Jaguar8 OP Lnova : It may get a delayed market reaction
Lnova Jaguar8 OP : I got in lower thanks to seeing your post about it
Lnova : It’s kinda going ?